Exelixis Inc (EXEL) 9.18 $EXEL Keryx (KERX) Q2 Earnings

New Post Public Reply Private Reply Replies (0) Message Board

Jul 31, 2016 at 11:00 PM

Exelixis Inc (EXEL) 9.18 $EXEL

Keryx (KERX) Q2 Earnings Preview: Will the Stock Gain?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 4:13PM CDT
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report second-quarter 2016 results on Aug 3.
IPXL: 31.42 (-0.05), IRWD: 14.13 (-0.21), KERX: 7.36 (unch), EXEL: 9.18 (+0.23)

What's in Store for Prothena (PRTA) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:44PM CDT
Prothena Corporation plc (PRTA) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 31.42 (-0.05), IRWD: 14.13 (-0.21), PRTA: 55.05 (-0.36), EXEL: 9.18 (+0.23)

Pfizer (PFE) Likely to Beat Earnings in Q2 Again
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 2:51PM CDT
Pfizer (PFE), which is set to report second-quarter 2016 results on Aug 2, had delivered a positive earnings surprise of 21.82% last quarter. Will it beat estimates again?
BMRN: 99.42 (+1.22), PFE: 36.89 (+0.22), ICPT: 173.03 (+6.13), EXEL: 9.18 (+0.23)

Learn how to target a 12% return on Exelixis, or get option-trade ideas on FireEye, Baidu, Marathon Petroleum Corporation and First Solar or any stock you choose
PR Newswire - Fri Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BIDU, EXEL, FEYE, FSLR, and MPC.
FSLR: 46.68 (-0.45), FEYE: 17.42 (-0.67), BIDU: 159.60 (-6.03), MPC: 39.39 (+1.22), EXEL: 9.18 (+0.23)

Whta's in Store for Endocyte (ECYT) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Endocyte, Inc. (ECYT) is expected to report second-quarter 2016 results on Aug 2.
IPXL: 31.42 (-0.05), ECYT: 3.18 (unch), IRWD: 14.13 (-0.21), EXEL: 9.18 (+0.23)

Mallinckrodt (MNK) Q3 Earnings: Will the Stock Surprise?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:47PM CDT
Mallinckrodt plc (MNK) is set to report third-quarter fiscal 2016 results on Aug 2.
MNK: 67.34 (unch), IRWD: 14.13 (-0.21), MDCO: 39.11 (+0.22), EXEL: 9.18 (+0.23)

77.0% Return Seen to Date on SmarTrend Exelixis Call (EXEL)
Comtex SmarTrend(R) - Tue Jul 26, 12:14AM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 3 months, Exelixis has returned 77.03% as of today's recent price of $8.71.
EXEL: 9.18 (+0.23)

McKesson (MCK) Q1 Earnings: Stock Likely to Beat?
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 5:35PM CDT
McKesson Corporation (MCK) is scheduled to report first-quarter fiscal 2017 results on Jul 27, after the market closes.
MCK: 194.56 (+1.12), IRWD: 14.13 (-0.21), BMY: 74.81 (+0.15), EXEL: 9.18 (+0.23)

Exelixis Rises 2.37% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Jul 15, 2:56PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $8.19 to a high of $8.47. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $8.27 on volume of 2.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 9.18 (+0.23)

Learn how to target a 20% return on Gilead Sciences, or get option-trade ideas on Aetna, Exelixis, Priceline and Abbott Laboratories or any stock you choose
PR Newswire - Thu Jul 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABT, AET, EXEL, GILD, and PCLN.
ABT: 44.75 (+0.30), GILD: 79.47 (-1.77), AET: 115.21 (-0.58), PCLN: 1,350.81 (+24.71), EXEL: 9.18 (+0.23)

Pfizer Reports Positive Data on Kidney Cancer Drug Sutent
Zacks Equity Research - Zacks Investment Research - Mon Jul 11, 8:23AM CDT
Pfizer Inc. (PFE) announced positive results from the phase III study, S-TRAC, on kidney cancer drug Sutent.
ABT: 44.75 (+0.30), PFE: 36.89 (+0.22), EXEL: 9.18 (+0.23), NVS: 83.26 (+1.18)

Biotechnology Equities Under the Scanner - Exelixis, Novavax, Celgene, and Ariad Pharma
PR Newswire - Thu Jul 07, 7:00AM CDT
On Wednesday, July 06, 2016, the NASDAQ Composite ended the trading session at 4,859.16, up 0.75%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 17,918.62; and the S&P 500 closed at 2,099.73, up 0.54%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Celgene Corporation (NASDAQ: CELG), and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA). Learn more about these stocks by accessing their free notes at:
NVAX: 7.32 (-0.06), ARIA: 9.51 (+0.04), CELG: 112.19 (+0.93), EXEL: 9.18 (+0.23), CELGZ: 1.16 (-0.01)

Exelixis Has Returned 58.9% Since SmarTrend Recommendation (EXEL)
Comtex SmarTrend(R) - Thu Jun 23, 12:51PM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 2 months, Exelixis has returned 58.94% as of today's recent price of $7.82.
EXEL: 9.18 (+0.23)

Exelixis Shares Up 50.0% Since SmarTrend's Buy Recommendation (EXEL)
Comtex SmarTrend(R) - Thu Jun 16, 12:23AM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 2 months, Exelixis has returned 50.00% as of today's recent price of $7.38.
EXEL: 9.18 (+0.23)

Exelixis Shares Up 45.1% Since SmarTrend's Buy Recommendation (EXEL)
Comtex SmarTrend(R) - Wed Jun 08, 12:57PM CDT
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on April 26th, 2016 at $4.92. In approximately 1 month, Exelixis has returned 45.12% as of today's recent price of $7.14.
EXEL: 9.18 (+0.23)

Exelixis Up on Positive Kidney Cancer Data on Cabometyx
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 2:46PM CDT
Exelixis, Inc. (EXEL), along with its partner Ipsen, announced positive data from subgroup analyses of the METEOR trial on Cabometyx
ABT: 44.75 (+0.30), JNJ: 125.23 (+0.77), PFE: 36.89 (+0.22), EXEL: 9.18 (+0.23)

Exelixis (EXEL) Shows Strength: Stock Moves 11.2% Higher
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:15AM CDT
Exelixis, Inc. (EXEL) shares rose over 11% in the last trading session.
ANIP: 60.60 (+0.99), EXEL: 9.18 (+0.23)

Roche Presents Encouraging Data on Actemra and Tecentriq
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:49PM CDT
Roche Holding AG (RHHBY) announced positive results from the phase III study, GiACTA, on arthritis drug, Actemra/RoActemra.
PFE: 36.89 (+0.22), BMY: 74.81 (+0.15), EXEL: 9.18 (+0.23)

SmarTrend Watching for Potential Pullback in Shares of Exelixis After 8.35% Gain
Comtex SmarTrend(R) - Mon Jun 06, 2:44PM CDT
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $6.76 to a high of $7.34. Yesterday, the shares gained 8.3%, which took the trading range above the 3-day high of $6.80 on volume of 10.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
EXEL: 9.18 (+0.23)

Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX(TM) (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting
BusinessWire - Mon Jun 06, 6:36AM CDT
--ABSTRACT #4557, #4558
EXEL: 9.18 (+0.23)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...

Honeywell Aerospace Faces Legal Turbulence in Fraud Case

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Navigating Battery Compliance for AI Data Centers

Untangling the Web of Global Battery Compliance Amid clamor about AI's insatiable appetite for energy storage, the rules around shipping, installing, and handling data center batteries have become a tangled web. From Waxahachie, Texas, Americase International plans to take the stage at the OCP Global Summit on October 15, 2026, to spearhead a discussion on bridging the...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....